Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,532.00
Bid: 7,531.00
Ask: 7,533.00
Change: 38.00 (0.51%)
Spread: 2.00 (0.03%)
Open: 7,517.00
High: 7,548.00
Low: 7,500.00
Yest. Close: 7,494.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 1-AstraZeneca smashes forecasts in Q2 after seeing off Pfizer

Thu, 31st Jul 2014 06:46

* Q2 revenue $6.45 billion vs consensus $6.29 billion

* Q2 core EPS $1.30 vs consensus $1.10

* Drugmaker raises full-year guidance

* Now assuming generic Nexium in U.S. from Oct. 1 (Adds detail on products, background)

By Ben Hirschler

LONDON, July 31 (Reuters) - AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

On the back of the strong results, AstraZeneca raised its guidance for the full year, predicting sales would hold steady and not decline as previously expected.

Chief Executive Pascal Soriot has fought hard to prove AstraZeneca has a strong independent future and does not need the kind of mega-merger offered by Pfizer.

He has gained credit for his firm's pipeline of promising new cancer drugs, while the respiratory business has been boosted by strong demand for Symbicort, which has taken business from GlaxoSmithKline's rival drug Advair.

AstraZeneca moved to boost its lung drug franchise further on Wednesday by acquiring rights to Spanish group Almirall's lung treatments in a deal worth up to $2.1 billion.

Sales in the first quarter rose 4 percent to $6.45 billion, despite generic competition to some drugs, generating "core" earnings, which exclude certain items, up 8 percent at $1.30 a share.

Industry analysts, on average, had forecast sales in the quarter of $6.29 billion and earnings of $1.10 a share, according to Thomson Reuters.

A raft of patent expiries will pressure sales and profits until at least 2017 but Britain's second-biggest pharmaceuticals group is enjoying a partial reprieve for now, due to the delayed U.S. launch of a generic form of heartburn pill Nexium.

Revenue in 2014 is now expected to be in line with 2013 at constant exchange rates - an increase on previous guidance of a low-to-mid single digit percentage decline - and core earnings per share are set for a low double-digit decline, against previous guidance of a percentage decrease in the teens.

AstraZeneca now assumes, for planning purposes, that generic versions of prescription Nexium will reach the U.S. market on Oct. 1.

India's Ranbaxy Laboratories holds the rights to sell the first generic copy of the popular drug but its continuing problems with meeting regulatory standards in manufacturing have delayed a launch.

AstraZeneca's quarterly results were also boosted by a $200 million milestone payment from Pfizer, following the U.S. company's launch of an over-the-counter version of Nexium in May. (Reporting by Ben Hirschler; editing by Tom Pfeiffer)

More News

Sri Lanka reports six cases of blood clots among AstraZeneca vaccine recipients, 3 dead

NEW DELHI, April 21 (Reuters) - Sri Lanka has found six cases of blood clots among recipients of the AstraZeneca COVID-19 vaccine, three of whom have died, Health Minister Pavithra Waniarachchi told parliament on Wednesday.Nearly a million people ...

Today 08:48

India's Serum institute to sell AstraZeneca vaccine to private hospitals at $8/dose

NEW DELHI, April 21 (Reuters) - The Serum Institute of India said on Wednesday it would sell the AstraZeneca vaccine to the country's state governments at 400 rupees ($5.30) per dose and to private hospitals at 600 rupees ($7.95)."Furthermore, owi...

Today 08:15

UPDATE 1-J&J to cooperate in study of rare clots linked to COVID-19 vaccine, German scientist says

(Adds details of collaboration, scientific paper)By John MillerZURICH, April 20 (Reuters) - A German scientist studying extremely rare blood clots linked to AstraZeneca's COVID-19 vaccine said on Tuesday Johnson & Johnson has agreed to work with h...

20 Apr 21 20:35

UPDATE 2-J&J to cooperate in study of rare clots linked to COVID-19 vaccine, German scientist says

(Adds details on class of vaccines)By John MillerZURICH, April 20 (Reuters) - A German scientist studying extremely rare blood clots linked to AstraZeneca's COVID-19 vaccine said on Tuesday Johnson & Johnson has agreed to work with him on the rese...

20 Apr 21 20:35

German scientist: J&J to cooperate in study of rare clots linked to COVID-19 vaccine

ZURICH, April 20 (Reuters) - A German scientist studying rare blood clots linked to AstraZeneca's COVID-19 vaccine said on Tuesday that Johnson & Johnson had agreed to collaborate with him on research into similar events associated with its own C...

20 Apr 21 17:54

European Medicines Agency: More than 300 cases of rare blood clot events worldwide

AMSTERDAM, April 20 (Reuters) - The European Union's drug regulator said on Tuesday there had been more than 300 cases worldwide of rare blood clotting incidents combined with low platelet counts after use of COVID-19 vaccines.There were 287 occur...

20 Apr 21 16:22

UPDATE 1-Mexico president receives AstraZeneca vaccine against COVID-19

(Adds context on AstraZeneca, quotes)MEXICO CITY, April 20 (Reuters) - Mexican President Andres Manuel Lopez Obrador received the AstraZeneca shot against COVID-19 on Tuesday, urging trust in vaccines after several countries limited the use of Ast...

20 Apr 21 15:54

UPDATE 2-Mexico president touts 'no risks' as he receives AstraZeneca vaccine

(Adds details on Mexico vaccine supply)By Daina Beth SolomonMEXICO CITY, April 20 (Reuters) - Mexican President Andres Manuel Lopez Obrador received the AstraZeneca shot against COVID-19 on Tuesday, urging trust in vaccines after several countries...

20 Apr 21 15:54

UPDATE 1-EU regulator finds possible link between J&J COVID-19 vaccine and blood clots

(Adds details from EMA statement)April 20 (Reuters) - Europe's drug regulator said on Tuesday it had found a possible link between Johnson & Johnson's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot in the Unite...

20 Apr 21 15:26

UPDATE 2-EU regulator backs J&J vaccine despite finding possible link to blood clots

* EMA assessed 8 cases of serious clots in the United States* Says overall benefits outweigh any risks* Cases occurred in adults under 60, most of them women (Writes through with details, background)April 20 (Reuters) - Europe's drug regulator has f...

20 Apr 21 15:26

UPDATE 3-EU regulator backs J&J shot, finds possible link to clots

* EMA assessed 8 cases of serious clots in the United States* Says overall benefits outweigh any risks* Cases occurred in adults under 60, most of them women (Adds details, quotes from EMA news conference)By Pushkala Aripaka and Anthony DeutschApril...

20 Apr 21 15:26

UPDATE 4-EU regulator backs J&J shot, finds possible link to clots

* EMA assessed 8 cases of serious clots in the United States* Says overall benefits outweigh any risks* Cases occurred in adults under 60, most of them women (Adding details throughout)By Pushkala Aripaka, Anthony Deutsch and John MillerApril 20 (Re...

20 Apr 21 15:26

UPDATE 5-EU regulator backs J&J shot, finds possible link to clots

* EMA assessed 8 cases of serious clots in the United States* Says overall benefits outweigh any risks* Cases occurred in adults under 60, most of them women (Adds details throughout)By Pushkala Aripaka, Anthony Deutsch and John MillerApril 20 (Reut...

20 Apr 21 15:26

Mexico president receives AstraZeneca vaccine against COVID-19

MEXICO CITY, April 20 (Reuters) - Mexican President Andres Manuel Lopez Obrador received the AstraZeneca vaccine against COVID-19 at his regular daily news conference on Tuesday.The 67-year-old, who had contracted the coronavirus in January, said ...

20 Apr 21 15:15

EU regulator finds possible link between J&J COVID-19 vaccine and blood clots

April 20 (Reuters) - Europe's drug regulator has found a possible link between Johnson & Johnson's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot in the United States, the watchdog said on Tuesday.(Reporting b...

20 Apr 21 15:12

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.